MetaCap

Haemonetics Corporation (HAE)

NYSE: HAEHealth CareMedical/Dental InstrumentsUSD

120.16-0.21 (-0.17%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

HAE stock chart

Technical analysis

Key statistics

All statistics
52-week range
51.00 – 132.00
Day range
119.68 – 122.00
Volume / Avg
382.95K / 659.70K
Beta
—

52-week range

$51.00$132.00

HAE stock today

Shares of Haemonetics (HAE) finished lower on Nov 20 at $120.16, a drop of 0.17% or $0.21 per share, versus the S&P 500's 3.70% decline. At this level, HAE sits near the top of its 52-week range of $51.00 to $132.00: 9.0% below the high, set on Nov 5, 2026 and 135.6% above the low. HAE is up 49.9% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 52.5%.

At 53.2x trailing earnings, Haemonetics trades in line with the peer-group median of 50.6x. Its forward P/E of 19.2x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About Haemonetics

Company profile

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools.

Industry
Medical/Dental Instruments
CEO
Mr. Christopher A. Simon
Headquarters
Boston, MA
Employees
3,009
IPO year
1991

Financial highlights

Full financials

In fiscal 2026, Haemonetics generated $1.33 billion in revenue, down 2.0% from fiscal 2025, its first annual decline since 2021. Net income was $97.3 million (-42.0% year over year), for a net margin of 7.3% versus a median of 9.1% in the prior 5 years. Gross margin was 59.0% (up from 55.0%) and operating margin 11.7%.

Haemonetics annual revenue, net income and EPS
Fiscal yearFY 2026FY 2025FY 2024FY 2023FY 2022
Revenue$1.33B$1.36B$1.31B$1.17B$993.20M
Growth-1.97%+3.95%+12.01%+17.67%+14.10%
Net income$97.31M$167.68M$117.56M$115.40M$43.38M
EPS (diluted)$2.05$3.31$2.29$2.24$0.84

Analyst forecast

Forecast

Consensus (12 analysts)

buy

Avg. price target

$147.18+22.49%

  • Strong buy 4
  • Buy 6
  • Hold 2
  • Sell 0
  • Strong sell 0

Target range

Low $125.00High $165.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$1.00 vs $1.30
Surprise
-23.08%

HAE news

All HAE news

Haemonetics peers

Health Care sector
HAE peer companies
CompanyPrice% ChgMarket capCompare
MMSIMerit Medical Systems Inc.84.34-0.08%$5.05Bvs HAE
TFXTeleflex Incorporated161.58-1.11%$6.41Bvs HAE
MMEDMiniMed Group Inc.16.01-1.54%$4.50Bvs HAE
ICUIICU Medical Inc.172.52-1.84%$4.31Bvs HAE
STVNStevanato Group S.p.A.15.65-1.76%$4.27Bvs HAE
HTFLHeartflow Inc.46.69+4.62%$4.10Bvs HAE
NVSTEnvista Holdings Corporation22.91-1.55%$3.67Bvs HAE
PLSEPulse Biosciences Inc45.55+2.57%$3.35Bvs HAE

Indexes, lists and sector

Haemonetics stock FAQ

What is Haemonetics's stock price today?

HAE last traded at $120.16 as of Nov 20, 4:00 PM EST, down 0.17% on the day. Prices are delayed at least 15 minutes.

Does Haemonetics pay a dividend?

No. Haemonetics does not currently pay a regular cash dividend.

What is HAE's P/E ratio?

HAE trades at a trailing P/E ratio of 53.17 and a forward P/E of 19.17, compared with a median of 50.6 for its closest peers.

Who is Haemonetics's CEO?

Mr. Christopher A. Simon is the chief executive officer of Haemonetics Corporation, which has about 3,009 employees.

Has HAE ever split its stock?

Yes. The most recent HAE stock split was a 2-for-1 split on Dec 3, 2012, one of 2 splits on record.

What is the HAE 52-week high?

The 52-week high for HAE is $132.00 and the 52-week low is $51.00. The stock is currently 9.0% below its high.

Compare HAE